3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
147
Breast Neoplasms
108
Lung Neoplasms
92
Carcinoma, Non-Small-Cell Lung
77
Neoplasm Metastasis
68
Glioblastoma
68
Brain Neoplasms
64
Glioma
59
Pancreatic Neoplasms
45
Carcinoma, Renal Cell
43
Multiple Myeloma
41
Squamous Cell Carcinoma of Head and Neck
39
Colorectal Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
37
Neoplasms
34
Melanoma
32
Lymphoma
32
Carcinoma, Hepatocellular
32
Urinary Bladder Neoplasms
31
Ovarian Neoplasms
29
Astrocytoma
28
Sarcoma
25
Oropharyngeal Neoplasms
24
Lymphoma, Follicular
23
Central Nervous System Neoplasms
23
Rectal Neoplasms
22
Uterine Cervical Neoplasms
21
Triple Negative Breast Neoplasms
21
Mouth Neoplasms
21
Lymphoma, Non-Hodgkin
21
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Epirubicin
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Observation
2
Monatide (IMS 3015)
2
Metformin
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Complete Response
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT01956513
2013-10-08
ADC
Centre Jean Perrin
Phase NA
Withdrawn